CF PharmTech, Inc. (CF PharmTech, Inc., referred to as "CF PharmTech"), following the completion of the E round of 630 million financing in January, once again completed the F round of 360 million yuan financing, a total of nearly 1 billion financing within 6 months. This round of equity transaction is led by Boyuan Capital and CICC Capital, SAIC Hengxu, Gimpu M&A Fund, Wosen Investment and other well-known institutions to participate in the investment. At the same time, Feijun Capital, Yuan Ming Capital and other existing old shareholders continue to increase their shares. Yi Kai Capital acted as the exclusive financial advisor for Changfeng E and F two rounds of financing.

CF PharmTech, Inc . is a comprehensive pharmaceutical company committed to providing high-quality respiratory drugs to patients around the world. Since its inception, the company has focused on the development of global respiratory disease treatment drugs, and has established a complete R & D base for inhalation preparations and production facilities for the global high-end market.
With the development of industrialization and aging, respiratory diseases have become a common disease in the world. In China, the number of patients with asthma, COPD and rhinitis is estimated to exceed 300 million, and the patient population is still growing rapidly. In July 2019, the "Opinions of The State Council on the Implementation of Healthy China Action" issued by The State Council officially positioned chronic obstructive pneumonia (COPD) in China as one of the four major diseases that seriously affect the health of citizens and greatly affect the quality of life, along with tumor, cardiovascular disease and diabetes. Inhaled formulations are a very high barrier segment in the world and are also the gold standard medicine for the treatment of respiratory diseases. In order to provide Chinese people with reasonable prices and reliable quality products, CF PharmTech has brought together an international senior team engaged in the development of respiratory drug delivery technology for a long time. They have their own expertise and complement each other, and have cultivated a group of Chinese professional inhalation drug research and development and production of successor backbone. At present, the company has begun to actively layout the research and development of new drugs on the basis of consolidating the existing product research and development, and make continuous efforts for the sustainable development of the company and actively return to the society. Speaking about the transaction, Mr. Ding Wei, chairman of CICC Capital, said: "CF PharmTech is a leading inhaled preparation platform enterprise in China, and has achieved major breakthroughs in a number of product technology links, with one of the few full-dosage technology platforms in China and a comprehensive commercial layout of inhaled preparation drug pipelines. In the context of the huge base of domestic patients with respiratory diseases and the dominance of multinational pharmaceutical companies, there is a huge space for domestic inhalation preparation companies with excellent technology and cost advantages, and the trend is gradually clear. Changfeng has a comprehensive range of inhalant preparations, a clear commercialization path, and actively layout overseas markets while vigorously accelerating localization, all of which make us confident in the company's prospects." Penghui Chen, founding partner of Boyuan Capital, said: "The excellent strategic vision and execution of CF PharmTech's management team have made the company stand out on the track of inhaled preparations. Although the treatment of chronic respiratory diseases such as asthma and COPD in Europe and the United States has been widely used in the treatment of various inhalant products, but because of the history of drug development in China, technical barriers and other reasons, the treatment rate and drug use rate are at a low level despite the large number of patients. CF PharmTech has worked hard in the field of inhalation preparations for many years, overcome a series of technical difficulties, and a number of products have entered the late stage, and the company is about to enter a new harvest period. We believe that with the launch of a series of reasonably priced and high-quality inhaled products from CF PharmTech, inhaled products will benefit more patients at home and abroad."
As the investment banking advisor for this transaction, Mr. Li Gang, Partner of Yi Kai Capital, said, "We are very honored to help CF PharmTech complete two large-scale financing rounds in six months. Changfeng's strong financing ability shows investors' unique preference for high-end preparations, a pharmaceutical segment with a relatively balanced risk and return, under the current special global market environment. We continue to see the accumulation and advantages of CF PharmTech in this field, and believe that Changfeng can continue to grow rapidly into a great company." Mr. Zhang Xiao, Managing director of Yi Kai Capital, said: "Congratulations to Changfeng on successfully completing the landing of the E and F rounds of financing during the epidemic, which is also the largest financing in the field of inhalation preparations in China. We believe that the successful completion of this financing has further established Changfeng's leading position in the field of inhalation preparations."